Investopedia: Will Immunotherapy Disrupt The Oncology Market?

Goldman Sachs' recent list of eight "disruptive technologies" included new therapies to fight cancer, drugs that promise to u...

Investopedia: Better Margins Can't Hide Merck's Growth Challenges

In spite of pretty weak top-line results, pharma companies like Merck (NYSE: MRK ), Pfizer (NYSE: PFE ), and Bristol-Myers (NYSE: BMY ) ...

Seeking Alpha: How Bad Will The Partial Hold On Sovaprevir Be For Achillion?

Achillion ( ACHN ) investors got a huge piece of bad news on Monday evening, when this biotech virology specialist announced that its lea...

Investopedia: Amgen Puts Onyx Pharmaceuticals In Play

Funny how an unsolicited bid will suddenly alert Wall Street to the value of a strong biotech. While Onyx Pharmaceuticals (Nasdaq: ONXX )...

Seeking Alpha: Volcano Still Has Plenty To Prove

Volcano ( VOLC ) has never been shy about setting ambitious targets or pursuing a bold vision for the company's future. Unfortunately...

Seeking Alpha: Achillion May Be The Most Underrated Biotech Left

There are broadly two types of biotech investors - the Wile E. Coyote types who see bargains everywhere and charge bravely after them and t...

Seeking Alpha: Celldex Turning Into A Compelling Immunotherapy Biotech

"Shoulda, coulda, woulda" will probably be my investing epitaph. While there is no shortage of investment advice telling you that...

Investopedia: After A Good Run, Novartis Looks Fairly Valued

Like so many other pharmaceutical stocks, Novartis (NYSE: NVS ) has done pretty well for its shareholders over the past year and solidly be...

Investopedia: Roche, Reloaded

There's a saying that you'll hear used with perennially successful sports franchises – they don't rebuild, they reload. That co...

Investopedia: After A Big Rally, Pfizer Might Need Some Rest

Big Pharma has enjoyed an exceptional stretch of performance lately, reversing what had been a relatively rare period of underperformance ...

Investopedia: Adasuve Deal Is Very Good For Alexza, But What About Teva?

It was just a week when I wrote that Teva Pharmaceutical (NYSE: TEVA ) seemed undervalued on the basis of its probable free cash flow (FCF)...

Seeking Alpha: No News Becoming Bad News For Lexicon Pharmaceuticals

Normally you would think that having a differentiated and proprietary diabetes compound with solid supporting data would make a biotech re...

Seeking Alpha: Alkermes Still Not Getting Full Credit For Its Pipeline

Biotech is a strange world, one where investors often seem to prefer stories that are relatively weak on sales, earnings, and actual data. ...